BACKGROUND: Management of patients with autoimmune hemolytic anemia (AIHA) and reticulocytopenia remains challenging. CASE REPORTS: Two patients with decompensated AIHA who were receiving immunosuppressive drugs were treated with erythropoietin (EPO). Administration of EPO increased reticulocyte counts and hemoglobin concentrations in both cases. One patient completely recovered following a short course of treatment. Hemolysis could be compensated in the second patient using only mild doses of immunosuppressive drugs in combination with EPO. CONCLUSION: The administration of EPO should be considered in patients with therapy-refractory AIHA, particularly in the presence of reticulocytopenia.
BACKGROUND: Management of patients with autoimmune hemolytic anemia (AIHA) and reticulocytopenia remains challenging. CASE REPORTS: Two patients with decompensated AIHA who were receiving immunosuppressive drugs were treated with erythropoietin (EPO). Administration of EPO increased reticulocyte counts and hemoglobin concentrations in both cases. One patient completely recovered following a short course of treatment. Hemolysis could be compensated in the second patient using only mild doses of immunosuppressive drugs in combination with EPO. CONCLUSION: The administration of EPO should be considered in patients with therapy-refractory AIHA, particularly in the presence of reticulocytopenia.
Authors: Y Bertrand; J J Lefrere; G Leverger; A M Courouce; C Feo; M Clark; G Schaison; J P Soulier Journal: Lancet Date: 1985-08-17 Impact factor: 79.321
Authors: Bruno Fattizzo; Marc Michel; Anna Zaninoni; Juri Giannotta; Stephanie Guillet; Henrik Frederiksen; Josephine M I Vos; Francesca R Mauro; Bernd Jilma; Andrea Patriarca; Francesco Zaja; Anita Hill; Sigbiørn Berentsen; Wilma Barcellini Journal: Haematologica Date: 2021-02-01 Impact factor: 9.941
Authors: Donjete Simnica; Simon Schliffke; Christoph Schultheiß; Nicola Bonzanni; Lorenzo F Fanchi; Nuray Akyüz; Barbara Gösch; Christian Casar; Benjamin Thiele; Janina Schlüter; Ansgar W Lohse; Mascha Binder Journal: Front Immunol Date: 2019-08-21 Impact factor: 7.561